BofA analyst Jason Gerberry moves to No Rating on Intra-Cellular Therapies (ITCI) after the company announced it has entered a definitive merger agreement under which Johnson & Johnson (JNJ) will acquire it for $14.6B, or $132 per share. Given the agreement, the firm believes the stock is no longer trading on fundamentals.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Neutral from Outperform at Baird
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald
- Intra-Cellular downgraded to Hold from Buy at Needham